Never double a dose to make up what was missed. Tobramycin Inhalation Solution should be inhaled twice a day as close to 12 hours apart as possible and not less than 6 hours apart. A missed dose can be taken later than planned as long as it is at least 6 hours before the next dose. After taking your missed dose, go back to your regular dosing schedule.
No. Tobramycin Inhalation Solution should be taken twice a day by oral inhalation for 28 days, followed by 28 days off drug.
No. Tobramycin Inhalation Solution should not be mixed with any other medicine, including dornase alfa (Pulmozyme®) or hypertonic saline.
No. Tobramycin Inhalation Solution comes in sterile, single-use ampules that should be used completely.
Tobramycin Inhalation Solution can be taken before or after eating. However, if it causes coughing, you may wish to take Tobramycin Inhalation Solution before eating or 2 hours after eating.
Yes. However, it is best to use the PARI LC PLUS included with Kitabis Pak only for the Tobramycin Inhalation Solution included with your pak.
Yes. There are expiration dates stamped on each ampule. It is important to follow the stamped date and discard any ampules that expire.
Yes. Kitabis Pak is covered on most state Medicaid PDL programs as well as having excellent commercial coverage. See www.kitabis.com/patient-access for more information.
Yes. Co-Pay assistance is available for eligible patients. With commercial insurance, patients may be eligible to pay as little as $0 per prescription through the Kitabis Pak Co-Pay Assistance Program. *Eligibility restrictions apply.
Visit our Request More Info page to complete a quick form that will allow us to contact you directly with additional information about Kitabis Pak and the PARI LC PLUS.
Kitabis Pak (co-packaging of tobramycin inhalation solution and a PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
Do not take Kitabis Pak (Tobramycin Inhalation Solution) if you are allergic to tobramycin, or any of the ingredients in Kitabis Pak, or any aminoglycoside antibiotic.
Before taking Kitabis Pak, inform your health care provider if you have or have had any hearing problems (including noises in your ears such as ringing or hissing), hearing loss, your mother has had hearing problems after taking an aminoglycoside, you have been told you have certain gene variants related to hearing abnormalities inherited from your mother, dizziness, kidney problems, muscle weakness such as myasthenia gravis or Parkinson's disease, breathing problems such as wheezing, coughing or chest tightness, or have had an organ transplant. Before you inhale Kitabis Pak, inform your health care provider if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed. It is not known if Kitabis Pak will pass into breast milk.
Tell your health care provider about all the medicines you take. Taking Kitabis Pak with certain other medications can cause serious side effects. If you are taking Kitabis Pak, you should discuss with your health care provider if you should take other medicines that may harm your nervous system, kidneys or hearing, or diuretics (water pills) such as Edecrin® (ethacrynic acid), Lasix® (furosemide), mannitol, or urea.
Kitabis Pak can cause serious side effects including hearing loss or ringing in the ears (ototoxicity), worsening kidney problems (nephrotoxicity), worsening muscle weakness, harm to an unborn baby, and/or severe breathing problems (bronchospasm). Tell your health care provider right away if you have hearing loss or hear noises in your ears (such as ringing or hissing), develop vertigo, dizziness, difficulty with balance, shortness of breath with wheezing, or coughing or chest tightness. Your health care provider may do a blood test and urine test to check how your kidneys are working while you are taking Kitabis Pak.
The most common side effects of Kitabis Pak include cough, sore throat, productive cough, shortness of breath, coughing up blood, worsening of lung problems or cystic fibrosis, changes in your voice (hoarseness), altered taste, and rash. Tell your health care provider about any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full prescribing information.
This web site is intended for United States residents only.
Kitabis Pak (co-packaging of tobramycin inhalation solution and a PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
Do not take Kitabis Pak (Tobramycin Inhalation Solution) if you are allergic to tobramycin, or any of the ingredients in Kitabis Pak, or any aminoglycoside antibiotic.
Before taking Kitabis Pak, inform your health care provider if you have or have had any hearing problems (including noises in your ears such as ringing or hissing), hearing loss, your mother has had hearing problems after taking an aminoglycoside, you have been told you have certain gene variants related to hearing abnormalities inherited from your mother, dizziness, kidney problems, muscle weakness such as myasthenia gravis or Parkinson's disease, breathing problems such as wheezing, coughing or chest tightness, or have had an organ transplant. Before you inhale Kitabis Pak, inform your health care provider if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed. It is not known if Kitabis Pak will pass into breast milk.
Tell your health care provider about all the medicines you take. Taking Kitabis Pak with certain other medications can cause serious side effects. If you are taking Kitabis Pak, you should discuss with your health care provider if you should take other medicines that may harm your nervous system, kidneys or hearing, or diuretics (water pills) such as Edecrin® (ethacrynic acid), Lasix® (furosemide), mannitol, or urea.
Kitabis Pak can cause serious side effects including hearing loss or ringing in the ears (ototoxicity), worsening kidney problems (nephrotoxicity), worsening muscle weakness, harm to an unborn baby, and/or severe breathing problems (bronchospasm). Tell your health care provider right away if you have hearing loss or hear noises in your ears (such as ringing or hissing), develop vertigo, dizziness, difficulty with balance, shortness of breath with wheezing, or coughing or chest tightness. Your health care provider may do a blood test and urine test to check how your kidneys are working while you are taking Kitabis Pak.
The most common side effects of Kitabis Pak include cough, sore throat, productive cough, shortness of breath, coughing up blood, worsening of lung problems or cystic fibrosis, changes in your voice (hoarseness), altered taste, and rash. Tell your health care provider about any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full prescribing information.
This web site is intended for United States residents only.
Kitabis Pak is the first ever FDA-approved nebulized tobramycin convenience kit. Distributed by PARI, this unique drug + device combination ensures that patients get what they need for their treatment.
Read more about Kitabis Pak...2412 PARI Way
Midlothian, VA 23112 USA
Tel: 1-844-KITABIS (548-2247)
email: info@kitabis.com
© 2024 PARI Respiratory, Inc. All Rights Reserved.
Tobi® is a registered trademark of Novartis AG.
BETHKIS® is a registered trademark of Chiesi Farmaceutici, S.p.A.